This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luo, L.-Y. Articles by Diamandis, E. P. Search for Related Content PubMed PubMed Citation Articles by Luo, L.-Y. Articles by Diamandis, E. P.

The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis¹

Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada [L-Y. L., E. P. D.]; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, M5G 1L5 Canada [L-Y. L., E. P. D.]; Department of Gynecology, Gynecologic Oncology Unit, University of Turin, Turin, Italy [D. K., S. F., R. B., M. M.]; National Center for Scientific Research "Demokritos," IPC, Athens 15310, Greece [A. S.]; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Leuven, Belgium [M. v. G., I. V.]; Department of Obstetrics and Gynecology, University Hospital Groningen, Groningen, the Netherlands [H. d. B., A. G. J. v. d. Z.]; and Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland [A. H., U-H. S.]

	ABSTRACT

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Human kallikrein 10 (hK10) is a secreted serine protease that is highly expressed in ovarian tissue.We hypothesized that hK10 might represent a novel serological marker for ovarian cancer. We quantified by immunoassay, hK10 in sera from 97 normal women (controls), 141 patients with benign gynecologic diseases, and 146 patients with ovarian cancer. We then examined the diagnostic and prognostic value of this measurement in ovarian cancer. We found that normal serum hK10 ranged from 50 to 1040 ng/liter (mean = 439 ng/liter). hK10 concentration is significantly elevated in serum of presurgical ovarian cancer patients (range: 106–11,746 ng/liter; mean = 1067 ng/liter) but not in serum of patients with benign gynecologic diseases (range: 120–1200 ng/liter; mean = 447 ng/liter). When a cutoff of 700 ng/liter was selected (diagnostic specificity = 90%), the diagnostic sensitivity for ovarian cancer is 54%. About 35% of CA125-negative ovarian cancer patients (CA125 < 23 kU/liter) were hK10 positive at 90% specificity. In patients with stage I/II ovarian cancer, use of these two markers in combination results in a 21% increase in sensitivity, at 90% specificity, compared with CA125 alone. High serum hK10 was strongly associated with serous epithelial type, late-stage, advanced grade, large residual tumor (>1 cm), suboptimal debulking, and no response to chemotherapy (all Ps < 0.001). In univariate Cox survival analysis, high serum hK10 is associated with increased risk for relapse and death (hazard ratio = 2.59 and 3.15, respectively, P 0.003). This prognostic value remains significant for overall survival in the multivariate analysis. Kaplan-Meier survival curves demonstrated similar findings. Serum hK10 represents a novel biomarker for ovarian cancer. We conclude that preoperative serum hK10 concentration is a strong and independent unfavorable prognostic marker for ovarian cancer.

	INTRODUCTION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Ovarian cancer is the most lethal gynecologic malignancy among North American women. Poor survival rates are mainly attributable to late diagnosis. Most patients at diagnosis have stage III/IV disease. The 5-year survival rate for stage III/IV ovarian cancer is only 25%, but for stage I/II disease, survival can be as high as 90%. CA125, the most widely used marker for ovarian cancer diagnosis, was discovered 20 years ago (1) . The major disadvantages of this marker include poor sensitivity and specificity for ovarian cancer, especially for diagnosis of early-stage disease. In stage I/II ovarian cancer, 40–50% of patients are CA125 negative and high serum CA125 is also seen in many benign gynecologic diseases and other types of cancer (2) . Therefore, there is an urgent need for new biomarkers for ovarian cancer.

Human kallikreins are secreted serine proteases, encoded by a group of genes tandemly localized on chromosome 19q13.3-4 (3) . Initially, this gene family in humans was considered to have only three members, encoding for hK1 (pancreatic/renal kallikrein), hK2 (human glandular kallikrein), and hK3 (widely known as prostate-specific antigen). Twelve new members have recently been identified, and they are designated as hK4, hK5 ... hK15. Human kallikreins have diverse physiological functions such as skin shedding, activation of growth factors, activation of other proteases, digestion of growth factor binding proteins, and maintenance of neural plasticity. This family also contributes the best-known marker for prostate cancer, prostate-specific antigen (3) .

hK10³ (also known as the normal epithelial cell-specific 1, NES1) is one of the newly identified members of the kallikrein family. It was cloned by subtractive hybridization by virtue of its down-regulation in a radiation-transformed breast cancer cell line (4) . The gene encoding for hK10 (designated as KLK10) is 5.5 kb in length and is formed of five coding exons (5) . Because the catalytic triad (histidine, aspartic acid, serine) specific for serine proteases is completely conserved in hK10, it is predicted to have trypsin-like serine protease activity. KLK10 is down-regulated in breast and prostate cancer cell lines and in testicular carcinoma (6 , 7) . Overexpression of KLK10 can suppress tumor growth in nude mice (6) . These findings suggest that hK10 may participate in cell growth control pathways.

hK10 is highly expressed in the ovary (4) . Because hK10 is a secreted protein, we hypothesized that its expression might be altered in ovarian cancer and that it may represent a novel biomarker for ovarian cancer. To examine this hypothesis, we first developed a highly sensitive and specific hK10 immunoassay (8) . With this method, we were able to quantify hK10 in various biological fluids and tissue extracts (8) . We found that hK10 was highly elevated in ovarian tumor cytosols and that this elevation was associated with poor patient prognosis (9) . In another preliminary investigation, hK10 was found to be elevated in sera from ovarian cancer patients but not in normal healthy controls or patients with other types of cancer (10) . In this study, we assess in detail the value of hK10 as a serological biomarker for ovarian cancer diagnosis and prognosis.

	MATERIALS AND METHODS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Production and Purification of Monoclonal Antibodies against hK10.
Previously, we reported production and purification of human recombinant hK10 from yeast and generation of polyclonal anti-hK10 antibodies (8) . To produce monoclonal antibodies against hK10, the splenocytes from the immunized mice were fused with the Sp2/0 myeloma cells using polyethylene glycol 1500. The fused cells were cultured in 96-well plates in DMEM (Life Technologies, Inc., Gaithersburg, MD) containing 20% FCS, 200 mM glutamine, 1% OPI (oxaloacetic acid, pyruvic acid, insulin), and 2% HAT (hypoxanthine, aminopterin, thymidine; Sigma Chemical Co., St. Louis, MO) for selection at 37°C, 5% CO₂ for 10–14 days. The supernatants were collected and screened for positive clones, which were then expanded sequentially in 24-well plates and 6-well plates in complete media (reducing the FCS to 15% and changing the HAT to HT). Subsequently, isotyping was performed to isolate clones producing anti-hK10 monoclonal antibodies of the IgG class. The monoclonals were then expanded in flasks to generate large amounts of supernatant in serum-free media (CD-1 media; Life Technologies, Inc.) containing 200 mM glutamine. Anti-hK10 monoclonal antibodies were purified from the culture supernatant with a protein G column (Amersham Pharmacia Biotech, Piscataway, NJ) according to manufacturer’s instructions.

Immunofluorometric Assay for hK10.
By incorporating two monoclonal anti-hK10 antibodies, a sandwich-type, one-step immunofluorometric assay for hK10 was developed. White polystyrene microtiter plates were first coated with one monoclonal anti-hK10 antibody (code B14) by incubating overnight 100 µl/500 ng/well of antibody diluted in a 50 mmol/liter Tris buffer (pH 7.80). The plates were then washed six times with washing buffer [containing 9 g/liter NaCl and 0.5 g/liter Tween 20 in 10 mmol/liter Tris buffer (pH 7.40)]. One hundred µl of hK10 standards or samples were applied into each well. One hundred µl of another biotinylated monoclonal anti-hK10 antibody (code 5D3) diluted 1000-fold in assay buffer [containing 60 g/liter BSA, 50 mmol/liter Tris (pH 7.80), 0.5 g/liter sodium azide, 2.5% normal mouse serum, 10% normal goat serum, and 1% bovine IgG) were also pipetted into each well (50 ng of antibody/well). The mixture was then incubated for 2 h with shaking and washed with washing buffer for six times. Subsequently, the plates were incubated with 100 µl/well alkaline phosphatase-conjugated streptavidin (Jackson Immunoresearch) diluted 20,000-fold in a diluent containing 60 g/liter BSA, 50 mmol/liter Tris (pH 7.80), and 0.5 g/liter sodium azide for 15 min and washed as described above. Finally, 100 µl of 1 mM diflunisal phosphate diluted in substrate buffer [0.1 M Tris (pH 9.1), 0.1 M NaCl, and 1 mM MgCl₂) were added into each well and incubated for 10 min. One hundred µl of developing solution (1 M Tris base, 0.4 M NaOH, 2 mM TbCl₃, and 3 mM EDTA) were pipetted into each well and mixed for 1 min. The fluorescence was measured with a time-resolved fluorometer, the CyberFluor 615 Immunoanalyzer (MDS Nordion, Kanata, Ontario, Canada). More details have been published elsewhere (11) .

Patient Population.
Included in this study were 97 apparently healthy women (ages 26–72 years; mean = 52 years, median = 49 years), 141 women with benign gynecologic diseases (ages 21–76 years; mean = 46 years, median = 45 years), and 146 patients with histologically confirmed primary ovarian carcinoma (ages 28–78 years; mean = 56 years, median = 57 years). Of the benign lesions, 50 were classified as endometriosis, 22 as mucinous cystadenomas, 10 as benign ovarian teratomas, 26 as ovarian dermoid cysts, 15 as corpus luteum, and 18 as serous cystadenomas. Tumors were staged according to the International Federation of Gynecology and Obstetrics criteria. Histological classification was based on the WHO and International Federation of Gynecology and Obstetrics recommendations. The characteristics of the ovarian cancer patients included stage, grade, histological type, postsurgery residual tumor, debulking success and response to chemotherapy. Serum samples from all patients were collected presurgically, before initiation of therapy, and stored at -80°C until analysis. For 105 ovarian cancer patients, serum was also available 2–3 weeks after surgery.

Sera were obtained from the following four centers: The Gynecologic Oncology Unit, University of Turin, Turin, Italy; the Department of Obstetrics and Gynecology, University Hospital Groningen, Groningen, the Netherlands; the Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Leuven, Belgium; and the Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland. Our protocols have been approved by the review boards of all participating institutions.

Patients were monitored for survival and disease progression for a median duration of 25 months (range: 1–106 months). Follow-up information was available for 131 of the ovarian cancer patients. Sixty-four (49%) of these relapsed and 28 (21%) died during the course of the follow-up period. All patients were treated with platinum-based chemotherapy and response to treatment was assessed as described elsewhere (12) .

Measurement of CA125.
CA125 was measured with a commercially available automated immunoassay method (Immulite 2000, Diagnostic Products Corporation, Los Angeles, CA). The upper limit of normal for this method is 23 kU/liter.

Statistical Analysis.
The nonparametric Mann-Whitney U test was used to determine differences between two groups, and the nonparametric Kruskal-Wallis test was used for the analysis of differences among more than two groups. These tests treated hK10 concentration in serum as a continuous variable. The analyses of differences between hK10 serum concentration before and after surgery were performed with the nonparametric McNemar test. The binomial distribution was used to compute the significance level of the McNemar test. Unconditional logistic regression models were developed to evaluate the ability of hK10 levels to predict presence of ovarian cancer. ROC curves were constructed for serum hK10 and CA 125 by plotting sensitivity versus (1-specificity), and the areas under the ROC curves were calculated. Correlation between different variables was assessed by Spearman correlation coefficient. hK10 serum concentration was also classified as either hK10 positive or hK10 negative. The relationship of this dichotomous variable to other clinicopathological correlates was established with the ² test or the Fisher’s exact test, as appropriate.

The impact of serum hK10 concentration on patient OS and on progression of the disease (PFS) was assessed with the HR, calculated by both univariate and multivariate Cox proportional hazards regression models. In the multivariate analysis, the clinical and pathological variables that may affect survival, including stage of disease, tumor grade, residual tumor, and histological type, were adjusted. Kaplan-Meier PFS and OS curves were also constructed to demonstrate the survival differences between the hK10-positive and hK10-negative patients. The log rank test was used to examine the significance of the differences among the survival curves.

	RESULTS

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 
Immunofluorometric Assay for hK10.
With two newly developed hK10-specific monoclonal antibodies, a noncompetitive, one-step immunoassay for hK10 was established. Compared with the previously reported assay (10) , the sensitivity of this assay is improved (detection limit of 0.02 µg/liter). The assay has no detectable cross-reactivity with other kallikreins (data not shown). Other assay characteristics were similar to those reported previously (8) .

Serum hK10 Concentration in Noncancer and Ovarian Cancer Patients.
The distributions of serum hK10 in normal controls, patients with benign gynecologic diseases, and presurgical ovarian cancer patients are shown in Fig. 1 . Serum hK10 concentration is similar in normal controls and patients with benign gynecologic diseases (means and medians were 439 and 409 and 447 and 414 ng/liter for the two groups, respectively). However, serum hK10 concentration in presurgical ovarian cancer patients (mean = 1607 ng/liter and median = 756 ng/liter) is significantly elevated (Mann-Whitney test; P < 0.001). The distribution of serum CA125 concentration among normal, benign disease, and ovarian cancer patient groups is also shown in Fig. 1 . Unlike CA125, which is elevated in benign gynecologic diseases and ovarian cancer, serum hK10 concentration is only elevated in ovarian cancer patients.

View larger version (21K): [in this window] [in a new window]   Fig. 1. Distribution of serum hK10 (A) and CA125 (B) in normal controls, patients with benign gynecologic diseases, and patients with ovarian cancer. The boxplots display the 10th, 25th, 50th (bold horizontal line is the median), 75th, and 90th percentiles. Ps calculated by the Mann-Whitney test were found to be <0.001 between hK10 concentrations in cancer versus normal, <0.001 between cancer versus benign, and 0.97 between normal versus benign. For CA125, Ps were <0.001 between cancer versus normal, cancer versus benign, and normal versus benign groups.

Correlation between Serum hK10 and CA125 Concentration.
With Spearman correlation analysis, a weak correlation (r_s = 0.40) between serum hK10 and CA125 was observed. Clearly, in many samples, there was a great variability between hK10 and CA125 values.

Diagnostic Sensitivity and Specificity of Serum hK10 for Ovarian Cancer.
The sensitivity of serum hK10 for ovarian cancer diagnosis at 90% specificity is shown in Table 1 . ROC curves for hK10 and CA125, as well as their combination were also constructed. The areas under the curve (and their 95% confidence intervals) were 0.80 (0.73–0.85) for hK10, 0.79 (0.73–0.86) for CA125, and 0.84 (0.78–0.89) or their combination. The overall diagnostic sensitivities of hK10 and CA125 are similar, whereas their combination results in the highest area under the ROC curves.

Prognostic Value of Serum hK10 in Ovarian Cancer.
A cutoff of 843 ng/liter (95^th percentile of the hK10 concentration in normals) was selected to categorize patients as hK10 positive and hK10 negative. The relationship between serum hK10 concentration and various clinicopathological characteristics of ovarian cancer was examined by ² test or Fisher’s exact test, where appropriate. As shown in Table 2 , hK10 positivity is strongly associated with late stage disease (stage III/IV), advanced grade (grade 3), serous histological type, large residual tumor (>1 cm), suboptimal debulking, and no response to chemotherapy (all Ps < 0.001).

View larger version (18K): [in this window] [in a new window]   Fig. 2. Kaplan-Meier survival curves for ovarian cancer patients who are either serum hK10 positive or hK10 negative. N = number of patients. For discussion, see text.

	DISCUSSION

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

Serum hK10 is a novel biomarker for ovarian carcinoma. This biomarker is more specific for ovarian cancer than CA125 because elevations were not seen in benign diseases commonly associated with elevated CA125 levels (Fig. 1) . The diagnostic sensitivity of hK10 is comparable with the diagnostic sensitivity of CA125 at the same specificity cutoffs (Table 1) . Furthermore, hK10 can increase the sensitivity of CA125 at all stages of the disease, including stage I/II disease (Table 1) . As a result of the weak correlation between hK10 and CA125, there are still many patients with normal CA125 who have elevated hK10 levels (Table 1) . Thus, CA125 and hK10 can be combined to increase the diagnostic sensitivity of each of the biomarkers alone.

hK10, like CA125, is more frequently elevated in serous ovarian carcinoma than in endometrioid and mucinous carcinomas (Table 2) . Serum hK10 concentration is also more frequently elevated in late stage and higher grade disease. Serum hK10 is a powerful predictor of patient outcomes. Patients with preoperative hK10 concentration above the 95^th percentile of normals (843 ng/liter) have significantly worse prognosis than patients with low preoperative hK10 (Table 3 and Fig. 2 ). Serum hK10 concentration is a more powerful prognostic indicator that serum CA125. The prognostic value of CA125 disappears in multivariate analysis, whereas serum hK10 is an independent prognostic indicator of OS, as shown in the multivariate analysis.

The data of Table 3 regarding response to chemotherapy and the Kaplan-Meier curves of Fig. 2 suggest that serum hK10 analysis may assist physicians in selecting therapeutic options for the following reasons: (a) virtually all patients with high presurgical hK10 relapse within 6 years and most die (Fig. 2) . (b) Sixty-seven percent of patients who do not respond to chemotherapy have high presurgical hK10 (Table 2) . Thus, presurgically high hK10 is most frequently associated with patients who are refractory to current chemotherapeutic schemes and who are destined to relapse and die. These patients should be good candidates for clinical trials evaluating alternative treatments. More targeted clinical studies to address these issues are warranted.

Serum hK10 likely originates from tumor cells because postoperatively the levels are significantly decreased. In our previous study, examining the prognostic value of hK10 analysis in ovarian tumor extracts, we verified the overexpression of hK10 in tumor cells by immunohistochemistry and additionally provided evidence that intratumor hK10 concentration is also a strong predictor of poor prognosis (9) . Interestingly, many other members of the human kallikrein gene family, including KLK4 (mRNA), KLK5 (mRNA), hK6 (protein), KLK7 (mRNA), KLK8 (mRNA), KLK9 (mRNA), and hK11 (protein), have already been shown to have prognostic value in ovarian cancer (18) . Serine proteases not belonging to the kallikrein family have also been shown to have prognostic value in ovarian cancer, including trypsin, prostasin, hepsin, and testisin (18) . It has been known for years that many other proteolytic enzymes have prognostic value in many different cancers (19, 20, 21, 22) . The biological mechanisms of proteolytic enzyme involvement in cancer prognosis include their ability to degrade extracellular matrix, thus facilitating invasion and metastasis (23 , 24) . It seems likely that multiple members of the human kallikrein gene family are disregulated in ovarian cancer. It is thus possible that other members of this protease family may emerge as potential ovarian cancer biomarkers. If these proteases are involved in cancer progression, they may be suitable candidates as therapeutic targets. These possibilities merit additional investigation.

	FOOTNOTES

 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by the National Cancer Institute of Canada, the Italian Association for Cancer Research, and OncoTherapeutics, Inc., Toronto, Ontario, Canada.

² To whom requests for reprints should be addressed, at Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Avenue, Toronto, Ontario, M5G 1X5 Canada. Phone: (416) 586-8443; Fax: (416) 586-8628; E-mail: ediamandis{at}mtsinai.on.ca

³ The abbreviations used are: hK10, human kallikrein 10; OS, overall survival; PFS, progression-free survival; ROC, receiver operating characteristic; HR, hazard ratio.

Received 5/31/02. Accepted 1/ 3/03.

	REFERENCES

Top ABSTRACT INTRODUCTION MATERIALS AND METHODS RESULTS DISCUSSION REFERENCES

 

1. Bast R. C., Jr., Klug T. L., St. John E., Jenison E., Niloff J. M., Lazarus H., Berkowitz R. S., Leavitt T., Griffiths C. T., Parker L., Zurawski V. R., Knapp R. C. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 309: 883-887, 1983.[Abstract]
2. Bast R. C., Jr., Xu F. J., Yu Y. H., Barnhill S., Zhang Z., Mills G. B. CA 125: the past and the future. Int. J. Biol. Markers, 13: 179-187, 1998.[Medline]
3. Yousef G. M., Diamandis E. P. The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr. Rev., 22: 184-204, 2001.[Abstract/Free Full Text]
4. Liu X. L., Wazer D. E., Watanabe K., Band V. Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res., 56: 3371-3379, 1996.[Abstract/Free Full Text]
5. Luo L., Herbrick J. A., Scherer S. W., Beatty B., Squire J., Diamandis E. P. Structural characterization and mapping of the normal epithelial cell-specific 1 gene. Biochem. Biophys. Res. Commun., 247: 580-586, 1998.[Medline]
6. Goyal J., Smith K. M., Cowan J. M., Wazer D. E., Lee S. W., Band V. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res., 58: 4782-4786, 1998.[Abstract/Free Full Text]
7. Luo L. Y., Rajpert-De Meyts E. R., Jung K., Diamandis E. P. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. Br. J. Cancer, 85: 220-224, 2001.[Medline]
8. Luo L. Y., Grass L., Howarth D. J. C., Thibault P., On H., Diamandis E. P. Immunofluorometric assay of human kallikrein 10 and its identification in biological fluids and tissues. Clin. Chem., 47: 237-246, 2001.[Abstract/Free Full Text]
9. Luo L. Y., Katsaros D., Scorilas A., Fracchioli S., Piccinno R., Rigault de la Longrais I. A., Howarth D. J., Diamandis E. P. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin. Cancer Res., 7: 2372-2379, 2001.[Abstract/Free Full Text]
10. Luo L. Y., Bunting P., Scorilas A., Diamandis E. P. Human kallikrein 10: a novel tumor marker for ovarian carcinoma?. Clin. Chim. Acta, 306: 111-118, 2001.[Medline]
11. Christopoulos T. K., Diamandis E. P. Enzymatically amplified time-resolved fluorescence immunoassay with terbium chelates. Anal. Chem., 64: 342-346, 1992.[Medline]
12. Yousef G. M., Kyriakopoulou L. G., Scorilas A., Fracchioli S., Ghiringhello B., Zarghooni M., Chang A., Diamandis M., Giardina G., Hartwick W. J., Richiardi G., Massobrio M., Diamandis E. P. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res., 61: 7811-7818, 2001.[Abstract/Free Full Text]
13. Tuxen M. K., Soletormos G., Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat. Rev., 21: 215-245, 1995.[Medline]
14. Mills G. B., Bast R. C., Jr., Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J. Natl. Cancer Inst. (Bethesda), 93: 1437-1439, 2001.[Free Full Text]
15. Woolas R. P., Conaway M. R., Xu F., Jacobs I. J., Yu Y., Daly L., Davies A. P., O’Rriant K., Berchuck A., Soper J. T. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol. Oncol., 59: 111-116, 1995.[Medline]
16. Jacobs I. J., Skates S. J., MacDonald N., Menon U., Rosenthal A. N., Davies A. P., Woolas R., Jeyarajah A. R., Sibley K., Lower D. G., Oram D. H. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet, 353: 1207-1210, 1999.[Medline]
17. Skates S. J., Xu F. J., Yu Y. H., Sjovall K., Einhorn N., Chang Y., Bast R. C., Jr., Knapp R. C. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer (Phila.), 76: 2004-2010, 1995.[Medline]
18. Diamandis E. P., Yousef G. M. Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem., 48: 1198-1205, 2002.[Abstract/Free Full Text]
19. Shigemasa K., Underwood L. J., Beard J., Tanimoto H., Ohama K., Parmley T. H., O’Brien T. J. Overexpression of testisin, a serine protease expressed by testicular germ cells, in epithelial ovarian tumor cells. J. Soc. Gynecol. Investig., 7: 358-362, 2000.[Medline]
20. Tanimoto H., Yan Y., Clarke J., Korourian S., Shigemasa K., Parmley T. H., Parham G. P., O’Brien T. J. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res., 57: 2884-2887, 1997.[Abstract/Free Full Text]
21. Hirahara F., Miyagi E., Nagashima Y., Miyagi Y., Yasumitsu H., Koshikawa N., Nakatani Y., Nakazawa T., Udagawa K., Kitamura H., Minaguchi H., Mityazaki K. Differential expression of trypsin in human ovarian carcinomas and low-malignant-potential tumors. Gynecol. Oncol., 68: 162-165, 1998.[Medline]
22. Mok S. C., Chao J., Skates S., Wong K., Yiu G. K., Muto M. G., Berkowitz R. S., Cramer D. W. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J. Natl. Cancer Inst. (Bethesda), 93: 1458-1464, 2001.[Abstract/Free Full Text]
23. Matrisian L. M. Cancer biology: extracellular proteinases in malignancy. Curr. Biol., 9: R776-R778, 1999.[Medline]
24. Aznavoorian S., Murphy A. N., Stetler-Stevenson W. G., Liotta L. A. Molecular aspects of tumor cell invasion and metastasis. Cancer (Phila.), 71: 1368-1383, 1993.[Medline]

This article has been cited by other articles:

				Y. Zheng, D. Katsaros, S. J.C. Shan, I. R. de la Longrais, M. Porpiglia, A. Scorilas, N. W. Kim, R. L. Wolfert, I. Simon, L. Li, et al. A Multiparametric Panel for Ovarian Cancer Diagnosis, Prognosis, and Response to Chemotherapy Clin. Cancer Res., December 1, 2007; 13(23): 6984 - 6992. [Abstract] [Full Text] [PDF]

				N. D. Kirkpatrick, M. A. Brewer, and U. Utzinger Endogenous Optical Biomarkers of Ovarian Cancer Evaluated with Multiphoton Microscopy Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2048 - 2057. [Abstract] [Full Text] [PDF]

				M. W. McIntosh, Y. Liu, C. Drescher, N. Urban, and E. P. Diamandis Validation and Characterization of Human Kallikrein 11 as a Serum Marker for Diagnosis of Ovarian Carcinoma Clin. Cancer Res., August 1, 2007; 13(15): 4422 - 4428. [Abstract] [Full Text] [PDF]

				J. Dorn, M. Schmitt, R. Kates, B. Schmalfeldt, M. Kiechle, A. Scorilas, E. P. Diamandis, and N. Harbeck Primary Tumor Levels of Human Tissue Kallikreins Affect Surgical Success and Survival in Ovarian Cancer Patients Clin. Cancer Res., March 15, 2007; 13(6): 1742 - 1748. [Abstract] [Full Text] [PDF]

				I. Meinhold-Heerlein, D. Bauerschlag, Y. Zhou, L. M. Sapinoso, K. Ching, H. Frierson Jr., K. Brautigam, J. Sehouli, E. Stickeler, D. Konsgen, et al. An Integrated Clinical-Genomics Approach Identifies a Candidate Multi-Analyte Blood Test for Serous Ovarian Carcinoma Clin. Cancer Res., January 15, 2007; 13(2): 458 - 466. [Abstract] [Full Text] [PDF]

				M. H. Slagter, L. J.G. Gooren, W. de Ronde, A. Soosaipillai, A. Scorilas, E. J. Giltay, M. Paliouras, and E. P. Diamandis Serum and Urine Tissue Kallikrein Concentrations in Male-to-Female Transsexuals Treated with Antiandrogens and Estrogens Clin. Chem., July 1, 2006; 52(7): 1356 - 1365. [Abstract] [Full Text] [PDF]

				C. A. Borgono, T. Kishi, A. Scorilas, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 8 Protein Is a Favorable Prognostic Marker in Ovarian Cancer Clin. Cancer Res., March 1, 2006; 12(5): 1487 - 1493. [Abstract] [Full Text] [PDF]

				I. Simon, S. Zhuo, L. Corral, E. P. Diamandis, M. J. Sarno, R. L. Wolfert, and N. W. Kim B7-H4 Is a Novel Membrane-Bound Protein and a Candidate Serum and Tissue Biomarker for Ovarian Cancer Cancer Res., February 1, 2006; 66(3): 1570 - 1575. [Abstract] [Full Text] [PDF]

				H. Nagahara, K. Mimori, T. Utsunomiya, G. F. Barnard, M. Ohira, K. Hirakawa, and M. Mori Clinicopathologic and Biological Significance of Kallikrein 6 Overexpression in Human Gastric Cancer Clin. Cancer Res., October 1, 2005; 11(19): 6800 - 6806. [Abstract] [Full Text] [PDF]

				L. E. Graves, E. V. Ariztia, J. R. Navari, H. J. Matzel, M. S. Stack, and D. A. Fishman Proinvasive Properties of Ovarian Cancer Ascites-Derived Membrane Vesicles Cancer Res., October 1, 2004; 64(19): 7045 - 7049. [Abstract] [Full Text] [PDF]

				J. Dupont, M. K. Tanwar, H. T. Thaler, M. Fleisher, N. Kauff, M. L. Hensley, P. Sabbatini, S. Anderson, C. Aghajanian, E. C. Holland, et al. Early Detection and Prognosis of Ovarian Cancer Using Serum YKL-40 J. Clin. Oncol., August 15, 2004; 22(16): 3330 - 3339. [Abstract] [Full Text] [PDF]

				C. A. Borgono, I. P. Michael, and E. P. Diamandis Human Tissue Kallikreins: Physiologic Roles and Applications in Cancer Mol. Cancer Res., May 1, 2004; 2(5): 257 - 280. [Abstract] [Full Text] [PDF]

				T. Kishi, A. Soosaipillai, L. Grass, S. P. Little, E. M. Johnstone, and E. P. Diamandis Development of an Immunofluorometric Assay and Quantification of Human Kallikrein 7 in Tissue Extracts and Biological Fluids Clin. Chem., April 1, 2004; 50(4): 709 - 716. [Abstract] [Full Text] [PDF]

				A. Scorilas, C. A. Borgono, N. Harbeck, J. Dorn, B. Schmalfeldt, M. Schmitt, and E. P. Diamandis Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker J. Clin. Oncol., February 15, 2004; 22(4): 678 - 685. [Abstract] [Full Text] [PDF]

				C. A. Iacobuzio-Donahue, R. Ashfaq, A. Maitra, N. V. Adsay, G. L. Shen-Ong, K. Berg, M. A. Hollingsworth, J. L. Cameron, C. J. Yeo, S. E. Kern, et al. Highly Expressed Genes in Pancreatic Ductal Adenocarcinomas: A Comprehensive Characterization and Comparison of the Transcription Profiles Obtained from Three Major Technologies Cancer Res., December 15, 2003; 63(24): 8614 - 8622. [Abstract] [Full Text] [PDF]

				C. A. Borgono, L. Grass, A. Soosaipillai, G. M. Yousef, C. D. Petraki, D. H. C. Howarth, S. Fracchioli, D. Katsaros, and E. P. Diamandis Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer Cancer Res., December 15, 2003; 63(24): 9032 - 9041. [Abstract] [Full Text] [PDF]

				K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis PNAS, October 14, 2003; 100(21): 12343 - 12348. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Luo, L.-Y. Articles by Diamandis, E. P. Search for Related Content PubMed PubMed Citation Articles by Luo, L.-Y. Articles by Diamandis, E. P.